GlobeNewswire·Jun 4, 2026, 8:00 AM ET

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

SPRY

ARS Pharmaceuticals announced a collaboration with Drew Brees, a former NFL quarterback and 2026 Hall of Fame inductee, to educate the public on severe food allergies & treatment options.
The partnership aims to highlight the importance of epinephrine & preparedness for people living with Type I allergic reactions, which affect approximately 40 million people in the U.S.
Brees, who was diagnosed with peanut & other food allergies several years ago, emphasizes that avoidance strategies alone do not eliminate risk & that having neffy® (epinephrine nasal spray) ready is essential.
neffy is an FDA-approved, needle-free epinephrine nasal spray designed for the emergency treatment of allergic reactions, including anaphylaxis, in adults & children weighing at least 33 pounds.
The collaboration seeks to encourage informed conversations between patients, caregivers, & healthcare providers regarding epinephrine treatment options ahead of summer camps & the new school season.
Brees advocates for creating comprehensive emergency plans & communicating them to family, coaches, & teammates to ensure everyone knows how to respond during an allergic emergency.
neffy is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis, in patients weighing 33 lbs. or greater & requires carrying two doses due to the potential need for a second administration.
The press release notes that limitations of traditional auto-injectors, such as fear of needles & complexity, often cause delays in treatment despite the high prevalence of severe allergic reactions.
Common side effects of neffy include nasal discomfort, headache, throat irritation, chest congestion, nose bleeds, dizziness, nausea, & vomiting, with specific warnings for patients with certain underlying medical conditions.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering patients & caregivers to protect against allergic reactions that could lead to anaphylaxis through the commercialization of neffy.